retatrutide peptide fda approval Update: Eli Lilly's Game Changer Retatrutide triples weight loss in

As you can see from the side-by-side Figure below, the new trial (at left) replicates the previous one for symptomatic benefit and reduced physical limitations (Y-axis, corresponding to the Kansas City score) with the primary endpoint findings remarkably similar

The medication is a triple-agonist drug, meaning it mimics three appetite hormones: GLP-1, GIP, and glucagon

Instead, it mimics a naturally occurring hormone in your gut that communicates with your brain

The heatmap below illustrates how side effects differ across GLP-1 drugs, offering a snapshot of how people experience their GLP-1 medication in everyday life